Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Madrigal Pharmaceuticals, Inc. (MDGL : NSDQ)

• Company Description    Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-? agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia and high triglycerides; and MGL-3745, a thyroid hormone receptor-? agonist which are in pre-clinical trial stage. Madrigal Pharmaceuticals Inc., formerly known as Synta Pharmaceuticals Corp., is based in Fort Washington, Pennsylvania. Number of Employees: 528

• Price / Volume Information    Yesterday's Closing Price: $489.26 Daily Weekly Monthly 20 Day Moving Average: 384,943 shares Shares Outstanding: 22.71 (millions) Market Capitalization: $11,111.79 (millions) Beta: -1.04 52 Week High: $496.98 52 Week Low: $265.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 13.89% 10.90% 12 Week 32.29% 26.80% Year To Date 58.56% 38.60%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 200 BARR HARBOR DRIVE SUITE 200 - WEST CONSHOHOCKEN,PA 19428 USA ph: 267-824-2827 fax: 781-274-8228 ir@madrigalpharma.com http://www.madrigalpharma.com

• General Corporate Information    Officers William J. Sibold - President and Chief Executive Officer Julian C. Baker - Chair of the Board Mardi C. Dier - Chief Financial Officer Rebecca Taub - Director Fred B. Craves - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 558868105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/25/26 Share - Related Items Shares Outstanding: 22.71 Most Recent Split Date: 7.00 (0.03:1) Beta: -1.04 Market Capitalization: $11,111.79 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.23 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-10.79 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 43.93% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/25/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 17.76 Price/Cash Flow: - Price / Sales: 15.00 EPS Growth vs. Year Ago Period: -3.25% vs. Previous Quarter: -167.37% Sales Growth vs. Year Ago Period: 362.03% vs. Previous Quarter: 34.99% ROE 09/30/25 - -41.50 06/30/25 - -38.38 03/31/25 - -50.54 ROA 09/30/25 - -26.18 06/30/25 - -27.32 03/31/25 - -37.19 Current Ratio 09/30/25 - 3.44 06/30/25 - 5.11 03/31/25 - 5.91 Quick Ratio 09/30/25 - 3.26 06/30/25 - 4.78 03/31/25 - 5.58 Operating Margin 09/30/25 - -39.04 06/30/25 - -54.68 03/31/25 - -123.38 Net Margin 09/30/25 - -39.04 06/30/25 - -54.68 03/31/25 - -123.38 Pre-Tax Margin 09/30/25 - -39.04 06/30/25 - -54.68 03/31/25 - -123.38 Book Value 09/30/25 - 27.55 06/30/25 - 31.35 03/31/25 - 32.01 Inventory Turnover 09/30/25 - 0.63 06/30/25 - 0.47 03/31/25 - 0.41 Debt-to-Equity 09/30/25 - 0.54 06/30/25 - 0.17 03/31/25 - 0.17 Debt-to-Capital 09/30/25 - 35.19 06/30/25 - 14.54 03/31/25 - 14.24

Powered by Zacks Investment Research ©